Chemosensory receptor ligand-based therapies
Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.
1. A method of increasing the circulating concentration of one or more of GLP-1 (total), GLP-1 (active), PYY (total), PYY 3-36, and insulin in a subject comprising administering orally a composition comprising a non-nutritive sweet receptor agonist, wherein said composition is adapted to release said non-nutritive sweet receptor agonist to one or more regions of the intestine of a subject selected from the group consisting of the duodenum, jejunum, ileum, caecum, colon, rectum, and combinations thereof.
2. A method according to claim 1 , wherein said composition further releases at least some of said non-nutritive sweet receptor agonist in the stomach.
3. A method according to claim 1 , wherein said composition is adapted to release said non-nutritive sweet receptor agonist distal to the duodenum.
4. A method according to claim 1 , wherein said one or more regions of the intestine are the jejunum, ileum, caecum, colon, rectum, or combinations thereof.
5. A method according to claim 1 , wherein said composition releases said non-nutritive sweet receptor agonist at an onset of about 5 to about 45 minutes, about 105 to about 135 minutes, about 165 to about 195 minutes, about 225 to about 255 minutes, or a combination of times thereof following administration to said subject.
6. A method according to claim 1 , wherein said composition releases said non-nutritive sweet receptor agonist at an onset of about pH 5.0, about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, or combination thereof following administration to said subject.
7. A method according to claim 1 , wherein said composition further comprises a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a bile acid receptor ligand, or a combination thereof.
8. A method according to claim 1 , wherein said non-nutritive sweet receptor agonist is selected from the group consisting of sucralose, aspartame, Stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E, Rebaudioside F, Neotame, acesulfame-K, and saccharin.
9. A method according to claim 7 , wherein said bitter receptor ligand is selected from the group consisting of a flavanone, a flavone, a flavonol, a flavan, a phenolic flavonoid, an isoflavone, a limonoid aglycone, a glucosinolate or hydrolysis product thereof, and an organic isothiocyanate.
10. A method according to claim 7 , wherein said umami receptor ligand is selected from the group consisting of glutamate salt, glutamine, acetyl glycine, and aspartame.
11. A method according to claim 7 , wherein said fat receptor ligand is selected from the group consisting of a linoleic acid, an oleic acid, an omega-3 fatty acid, a palmitate, an oleoylethanolamide, a mixed fatty acid emulsion, and an N-acylphosphatidylethanolamine (NAPE).
12. A method according to claim 7 , wherein said bile acid receptor ligand is selected from the group consisting of deoxycholic acid, a taurocholic acid, and a chenodeoxycholic acid.
13. A method according to claim 1 , wherein said composition is administered prior to ingestion of food by said subject.
14. A method according to claim 1 , wherein said subject is undergoing bariatric surgery.
15. A method according to claim 1 , further comprising administration of a drug for diabetes or obesity.
16. A method according to claim 8 , wherein said non-nutritive sweet receptor agonist is Rebaudioside A.
17. A method according to claim 1 , wherein said composition further comprises an unami receptor agonist and a bitter receptor agonist.
18. A method according to claim 1 , wherein said composition is enterically coated.